SONN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.00%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Sonnet BioTherapeutics Insider Trading History Chart

Sonnet BioTherapeutics Share Price & Price History

^$2.90

▼ -0.02 (-0.68%)

As of 11/21/2024 01:00 AM ET

Days: 30 | 90 | 365

The Biggest Post-Election Market Shift Ever?

From Stansberry Research | Ad

Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.

Get our No. 1 stock (with 500%-plus upside potential) for this rare market event now.

Sonnet BioTherapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/14/2023	Susan Dexter	Insider	Buy	454	$15.40	$6,991.60	1,530
5/30/2023	Albert D Dyrness	Director	Buy	1,057	$10.34	$10,929.38	1,316
5/17/2023	Nailesh Bhatt	Director	Buy	1,136	$5.06	$5,748.16	1,396
5/15/2023	Pankaj Mohan	CEO	Buy	16,890	$4.84	$81,747.60	25,151

$2 Trillion Disappears Because of Fed's Secretive New Move

From Stansberry Research | Ad

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Click here to see his new research now.

SEC Filings (Institutional Ownership Changes) for Sonnet BioTherapeutics (NASDAQ:SONN)

9.45% of Sonnet BioTherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Sonnet BioTherapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/15/2024	Armistice Capital LLC	272,000	$0.26M	0.0%	N/A	8.740%
7/27/2023	Virtu Financial LLC	86,624	$42K	0.0%	N/A	0.315%
5/19/2023	Anson Funds Management LP	1,760,000	$0.63M	0.1%	N/A	6.405%
11/7/2022	Virtu Financial LLC	26,914	$40K	0.0%	N/A	0.622%
8/2/2022	Advisory Services Network LLC	130,525	$37K	0.0%	+158.3%	0.215%
5/10/2022	Campion Asset Management	90,612	$34K	0.0%	N/A	0.150%
8/16/2021	State Street Corp	62,688	$99K	0.0%	N/A	0.253%
8/13/2021	Vanguard Group Inc.	701,634	$1.11M	0.0%	+416.0%	2.834%
5/19/2021	Virtu Financial LLC	65,106	$0.15M	0.0%	N/A	0.371%
5/18/2021	Citadel Advisors LLC	113,264	$0.26M	0.0%	N/A	0.534%
5/18/2021	Jane Street Group LLC	17,304	$39K	0.0%	N/A	0.099%
5/17/2021	Price T Rowe Associates Inc. MD	45,100	$0.10M	0.0%	N/A	0.257%
5/13/2021	Bank of New York Mellon Corp	20,399	$46K	0.0%	N/A	0.116%
5/7/2021	BlackRock Inc.	255,761	$0.58M	0.0%	+3.7%	1.457%
3/26/2021	Susquehanna International Group LLP	15,434	$34K	0.0%	N/A	0.088%
2/9/2021	Advisory Services Network LLC	24,581	$55K	0.0%	+32.3%	0.143%
2/5/2021	BlackRock Inc.	246,555	$0.55M	0.0%	+2.5%	1.435%
11/19/2020	Schonfeld Strategic Advisors LLC	12,200	$31K	0.0%	N/A	0.071%
11/19/2020	IHT Wealth Management LLC	10,000	$26K	0.0%	N/A	0.058%
11/17/2020	Schonfeld Strategic Advisors LLC	12,200	$31K	0.0%	N/A	0.089%

Data available starting January 2016

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

Today's Range

Now: $2.90

$2.88

$3.08

50 Day Range

MA: $3.78

$0.71

$6.71

52 Week Range

Now: $2.90

$2.50

$18.72

Volume

60,789 shs

Average Volume

134,745 shs

Market Capitalization

$1.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Who are the company insiders with the largest holdings of Sonnet BioTherapeutics?: Sonnet BioTherapeutics' top insider investors include:
Pankaj Mohan (CEO)
Susan Dexter (Insider)
Nailesh Bhatt (Director)
Albert D Dyrness (Director)
Learn More about top insider investors at Sonnet BioTherapeutics.

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.